FILING ANALYSIS · THURSDAY, OCTOBER 29
INCYTE CORP INCY — 8-K: Results of Operations and Financial Condition
positive
Incyte's Q3 2026 results show a 14% increase in total revenue and net sales, driven by strong commercial performance and pipeline progress, with the company raising its full-year 2026 net sales guidance for Opzelura, Hematology and Oncology, and total net sales.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →